Kyowa Hakko President Yuzuru Matsuda : Speed is Key in Growing Globally
This article was originally published in PharmAsia News
Executive Summary
In an interview with Yakuji News, Kyowa Hakko President Yuzuru Matsuda said the company was moving faster to compete globally and achieve market leadership in antibody drugs. The antibody drug market reached ¥2,200 billion last year and is estimated to reach ¥4,500 billion by 2011. A merger with Kirin Pharma is expected to create synergy for the two companies that combine Kyowa's Potelligent technology and Kirin's KM mouse technology for creating humanized antibodies. This will boost efficiency in R&D and speed up new drug development, which Matsuda said was key for Kyowa. The company has three drugs in clinical trials: Kyowa's CCR4 antibody-KW-076, Medimmune's receptor antibody-BIW-8405, and Medarex's CD 30 antibody-MDX-1401. (Click for more-Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.